Understanding the gap between guidelines and influenza vaccination coverage in people with diabetes

A scoping review

Bibliographic Data

ID22078985
AuthorsBrice Mastrovito (0000-0002-7510-2429, Centre de Recherche Astrophysique de Lyon), Alexia Lardon (Centre de Recherche Astrophysique de Lyon), Amelie Dubromel (0000-0002-9679-0187, Centre de Recherche Astrophysique de Lyon), Viviane Nave (Centre de Recherche Astrophysique de Lyon), Karen Beny (0000-0003-1437-4276, Centre de Recherche Astrophysique de Lyon), Claude Dussart (0000-0002-1091-9139, Lyon 1 Université, corresponding author)
Year2024
Volume12
Pages1360556-1360556
Publication date2024-04-19
Open AccessYes
TypeARTICLE
VenueFrontiers in Public Health (JOURNAL)
Journal identifiersISSN: 2296-2565 • E-ISSN: 2296-2565
PublisherFrontiers Media SA (PUBLISHER • CH)
DOI10.3389/fpubh.2024.1360556
PMID38706547
OpenAlexW4394961290
LanguageEN
References cited105

Background: Diabetes affects millions of people worldwide, making them more vulnerable to infections, including seasonal influenza. It is therefore particularly important for those suffering from diabetes to be vaccinated against influenza each year. However, influenza vaccination coverage remains low in this population. This review primarily aims to identify the determinants of influenza vaccination in people with diabetes (T1D or T2D). Secondly, it aims to assess main recommendations for influenza vaccination, vaccine effectiveness, vaccination coverage, and how education and pharmacists can encourage uptake of the vaccine in the diabetic population. Methods: A scoping review was conducted in January 2022 to systematically review evidence on influenza vaccination in people with diabetes using data from PubMed, Science Direct, and EM Premium with terms such as "Diabetes mellitus," "Immunization Programs," "Vaccination," and "Influenza Vaccines." Quality assessment and data extraction were independently conducted by two authors. Disagreements between the authors were resolved through discussion and consensus, and if necessary, by consulting a third author. Results: Of the 333 records identified, 55 studies met the eligibility criteria for inclusion in this review. Influenza vaccination was recommended for people ≥6 months. Despite effectiveness evidence showing a reduction in mortality and hospitalizations in people with diabetes vaccinated vs. non-vaccinated ones, very few studies reported a coverage rate ≥ 75%, which is WHO's target objective. Determinants such as advanced age, presence of comorbidities and healthcare givers' advice were associated with increased vaccination uptake. On the contrary, fear of adverse reactions and concerns about vaccine effectiveness were significant barriers. Finally, education and pharmacists' intervention played a key role in promoting vaccination and increasing vaccination uptake. Conclusion: Influenza vaccination coverage in people with diabetes remains low despite recommendations and evidence on vaccine effectiveness. Motivators and barriers as well as several socio-demographic and clinical factors have been identified to explain this trend. Efforts are now needed to increase the number of diabetics vaccinated against influenza, mainly through education and the involvement of healthcare givers

Data science · Diabetes mellitus · Environmental health · Vaccination · Computer Science · Immune responses and vaccinations · Influenza Virus Research Studies · Medicine · Respiratory viral infections research · Immunology

Tools

Open DOIOpen Access